Too Old to Operate7h
Impact of Antibiotics on Immune Checkpoint Inhibitor Efficacy
The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...
clinicaladvisor.com4h
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Too Old to Operate2d
FLOT Chemotherapy Improves Overall Survival in Esophageal Adenocarcinoma
The following is a summary of “Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer,” published ...
HealthDay on MSN4d
Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma
For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ne ...
Targeted Oncology1h
ARANOTE Features Significant rPFS Benefit of Darolutamide/ADT in mHSPC
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...
FiercePharma1d
Roche's breast cancer entrant Itovebi bolsters clinical profile with overall survival win
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Positive Buy Rating for Cullinan Management Driven by Zipalertinib’s Promising Efficacy and Strategic Partnership with Taiho Oncology
JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of ...